Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Center-Al grass pollen extract is an alum-precipitated allergenic biologic used for allergen-specific immunotherapy. In the clinical trial context led by Amber Patterson, this extract is being evaluated for intralymphatic immunotherapy (ILIT) in adolescents and young adults with allergic rhinitis and rhinoconjunctivitis. ILIT involves the direct injection of the allergen into a lymph node to induce rapid immune tolerance, potentially offering a more efficient alternative to traditional subcutaneous immunotherapy (SCIT) by requiring fewer doses and lower allergen concentrations. The extract works by modulating the immune system's response to grass pollen, promoting the expansion of regulatory T cells and shifting the antibody profile from IgE-mediated allergic inflammation toward a protective IgG4-mediated response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Center-Al grass pollen extract.